Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
Clinical Pharmacology & Therapeutics · 2026-03 · 119 (3) · 608-617
DOI: 10.1002/cpt.70134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 23.11.2025. Verfasst von Tanja S Zabka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Genentech/Roche, South San Francisco, California, USA. Hauptthemen laut MEDLINE: Drug Development, Clinical Trials as Topic, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FDA HHS, Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS).
Abstract (Originalsprache)
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration. Since 2018, these qualified kidney injury urine biomarkers have been included in early clinical drug development programs. Drug‐induced kidney injury has historically contributed to high drug candidate attrition rates, additional animal testing needed due to the limitations of standard clinical laboratory tests in timely nephrotoxicity detection, and unsustainable development program fiscal costs. By illustrating the practical application, case studies from pharmaceutical companies illustrate how FDA‐qualified drug‐induced kidney injury biomarkers can enhance early detection and enable more sensitive and/or specific monitoring of nephrotoxicity. Moreover, data from completed trials registered on ClinicalTrials.gov show that the use of these non‐standard‐of‐care biomarkers as prespecified safety endpoints has increased since their qualification in 2018.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genentech/Roche, South San Francisco, California, USA.
- Critical Path Institute, Tucson, Arizona, USA.
- Global Patient Safety, AstraZeneca Ltd., Luton, UK.
- Merck & Co., Inc, Rahway, New Jersey, USA.
ORCID-Profile: Gary S Friedman, Katrina Peron, Nicholas M P King
Förderung
- FDA HHS
- Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS)
Zitieren
APA
Zabka, T. S., Lawton, M., Chu, T., Friedman, G. S., Peron, K., Sultana, S. R., Glaab, W. E., & King, N. M. P. (2026). Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development. Clinical Pharmacology & Therapeutics, 119(3), 608-617. https://doi.org/10.1002/cpt.70134
Vancouver
Zabka TS, Lawton M, Chu T, Friedman GS, Peron K, Sultana SR, et al. Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development. Clinical Pharmacology & Therapeutics. 2026;119(3):608-617. doi:10.1002/cpt.70134
BibTeX
@article{Zabka2026,
author = {Zabka, Tanja S and Lawton, Michael and Chu, Tom and Friedman, Gary S and Peron, Katrina and Sultana, Stefan R and Glaab, Warren E and King, Nicholas M P},
title = {Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {3},
pages = {608--617},
doi = {10.1002/cpt.70134}
}
EUVIMED